The notices it replaced
- Reissues: PA-22-178 PHS 2022-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
- 2 steps back: PA-21-262 PHS 2021-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
- 3 steps back: PA-20-265 PHS 2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
- 4 steps back: PA-19-270 PHS 2019-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed
- 5 steps back: PA-18-575 PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
- 6 steps back: PA-17-303 PHS 2017-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 7 steps back: PA-16-303 PHS 2016-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 8 steps back: PA-15-270 PHS 2015-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 9 steps back: PA-14-072 PHS 2014-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42]
- 10 steps back: PA-13-235 Reissue PHS 2013-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 11 steps back: PA-13-089 PHS 2013-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 12 steps back: PA-12-089 PHS 2012-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 13 steps back: PA-11-097 PHS 2011-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 14 steps back: PA-10-051 PHS 2010-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 15 steps back: PA-09-081 PHS 2009-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
Replaced by PA-24-247.
Who won it before
2,088 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $720,687,951 in first-year total cost, median $285,749.
Most frequent study sections
- Special Emphasis Panel[ZRG1 SBIB-T (10)]101
- Special Emphasis Panel[ZRG1 OTC-T (10)]81
- Special Emphasis Panel[ZRG1 ETTN-G (12)]62
- Special Emphasis Panel[ZRG1 ETTN-M (11)]55
- Special Emphasis Panel[ZRG1 BCMB-G (10)]52
Most frequent institutions
- FOX CHASE CHEMICAL DIVERSITY CENTER, INC19
- L2 DIAGNOSTICS, LLC17
- MEDOSOME BIOTEC, LLC11
- MICROBIOTIX, INC9
- ARREVUS, INC.8
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2025 | Improved Methods and Commercialization of a Multimodal Vibrating Sharp-Edge Spray Ionization Source2R42GM142379-02A1 | VALENTINE, STEPHEN | INVIBRAGEN INC., WV | $1,147,352 | ZRG1 |
| 2025 | Mitigation of Ionizing Irradiation-Induced Intestinal Damage by Second-Generation Probiotic LR-IFN-β2R42AI157357-03A1 | GREENBERGER, JOEL SROGERS, CLAUDE J. | CHROMOLOGIC, LLC, CA | $1,015,000 | ZRG1 |
| 2025 | Tacrolimus-eluting nerve guidance conduit for enhanced regeneration in critical-sized peripheral nerve injuries2R42NS112066-02 | AGARWAL, JAYANT PRASADAZAPAGIC, AZURGALE, BRUCESANT, HIMANSHUSHEA, JILL E | MICROSURGICAL INNOVATIONS, INC., UT | $919,846 | ZRG1 |
| 2025 | Manufacturing Process Intensification for Pluripotent Stem Cell-Derived Rare Red Cell Production1R41HL178144-01 | CHOU, STELLA TTHOMAS, ROBERT JAMES | SAFI BIOTHERAPEUTICS INC, MA | $568,264 | ZRG1 |
| 2025 | Commercialization of a phylogenetic cell separation method for downstream purification of nucleic acids2R42GM140530-02 | MARCIANO, MICHAELMCPIKE, MARK PATRICK | SYRACUSE BIOLABS, INC., NY | $510,862 | ZRG1 |
| 2025 | Promoting tissue repair and functional recovery after spinal cord injury by targeting the microtubule regulatory protein Fidgetin-like 2.1R41NS137941-01A1 | BAKER, LISA ANNBYRNES, KIMBERLY | MICROCURES, INC., CA | $458,154 | ZRG1 |
| 2025 | Development of a DISE-inducing, short RNA therapeutic to treat ovarian cancer1R42CA291346-01A1 | PETER, MARCUS E.SCHICKEL, ROBERT | NUAGO THERAPEUTICS INC, IL | $400,000 | ZRG1 |
| 2025 | Activating TFEB to enhance the efficacy of immunotherapy for triple negative breast cancer1R41CA298141-01 | FAN, DAPING | PROMILEAD, LLC, SC | $400,000 | ZRG1 |
| 2025 | Nanoparticle formulation of Mediator kinase inhibitor for the treatment of peritoneal ovarian cancer1R41CA298223-01 | CHEN, MENGQIANKARTHIKEYAN, MYTHREYE | SENEX BIOTECHNOLOGY, INC., SC | $400,000 | ZRG1 |
| 2025 | Optimized targeted radiotherapy of pancreatic cancer1R41CA284997-01A1 | MUKHERJEE, PINKUZHOU, RU | ONCOTAB, INC, NC | $400,000 | ZRG1 |
| 2025 | Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment1R41CA298754-01 | KANG, DONGKYUN | ARGOSMD, INC., CA | $400,000 | ZRG1 |
| 2025 | Development of NEO212, A Novel Oral Drug for the Treatment of Acute Myeloid Leukemia1R41CA271879-01A1 | CHEN, THOMAS C. | NEONC TECHNOLOGIES, INC., CA | $399,998 | ZRG1 |
| 2025 | Advancing cancer therapy: Developing antibody blockade targeting a novel immune checkpoint, LAIR1/CD3051R41CA298020-01 | HUANG, JIANPING | IMMUNOGENIK, INC., FL | $398,997 | ZRG1 |
| 2025 | RegendoGEL for guided pulp and dentin regeneration1R41DE033326-01A1 | BERTASSONI, LUIZ EDUARDOCRANE, MICHAELYELICK, PAMELA C | REGENDODENT, INC., MI | $398,785 | ZRG1 |
| 2025 | Investigating Abbapolin PLK1 Polo Box Domain inhibitors as potential therapeutics for colorectal cancers1R41CA298584-01 | MCINNES, CAMPBELL | PPI PHARMACEUTICALS, LLC, SC | $395,724 | ZRG1 |
| 2025 | Development of an immune evasive stem cell line for Type 1 diabetes regenerative therapy1R41DK142395-01 | SHEN, CHRISTOPHER | ALEUTIAN THERAPEUTICS, INC., CA | $372,067 | ZRG1 |
| 2025 | High-Resolution Pseudouridine and m6A Sequencing Through Advanced Nanopore Adduct Analysis1R41GM157757-01 | ERVIN, ERIC | ELECTRONIC BIOSCIENCES, INC., CA | $350,000 | ZRG1 |
| 2025 | Novel Extracorporeal Technology for Kidney Disease1R41DK139916-01A1 | JOY, MELANIE S | KATHAROS, INC., CO | $350,000 | ZRG1 |
| 2025 | Tolerogenic Nanotherapy to Delay Type I Diabetes1R41DK142265-01 | SCOTT, EVAN ALEXANDER | SNC THERAPEUTICS, INC., IL | $350,000 | ZRG1 |
| 2025 | Deep Reasoning AI Virtual Anatomical Technology & Augmented Reasoning Platform: Application to Craniomaxillofacial Reconstruction1R41DE034646-01 | CHEN, DIMORRIS, JONATHAN M | DEEP REASONING AI INC, FL | $350,000 | ZRG1 |
| 2025 | Spotting-free Nano-Oscillator Array for Quantification of Virion Displayed Membrane Protein Binding Kinetics1R42GM157918-01 | LY, NGUYEN | BIOSENSING INSTRUMENT, INC., AZ | $349,566 | ZRG1 |
| 2025 | Soft-Landing of Size-Separated Macromolecules for Structural Analysis by Cryo-TEM1R41GM157850-01 | PEREZ LORENZO, LUIS JAVIERRUOTOLO, BRANDON T | NANOENGINEERING CORPORATION, FL | $338,843 | ZRG1 |
| 2025 | Maternal Health Navigator intervention to reduce disparities in severe maternal morbidity and mortality1R41HD117656-01 | SURKAN, PAMELA JZACHARY, WAYNE W | STARSHIP HEALTH TECHNOLOGIES, PA | $321,341 | ZRG1 |
| 2025 | Advancing Native Mass Spectrometry Analysis with Easier, Faster and More Accurate Intact Mass Deconvolution for Proteins and Nucleic Acids1R41GM157865-01 | FREITAS, MICHAEL A. | MASSMATRIX, INC., OH | $316,825 | ZRG1 |
| 2025 | DelineateQSP: Accelerating Quantitative Systems Pharmacology Model Building and Repurposing1R41GM157892-01 | IQBAL, JAWAD | DELINEATE INC, MA | $314,363 | ZRG1 |
| 2025 | Next Generation Stealth Lipid for the Delivery of mRNA1R41AI181391-01A1 | CHILKOTI, ASHUTOSHHUCKNALL, ANGUS | GATEWAY BIO, INC., NC | $314,347 | ZRG1 |
| 2025 | Long-read sequencing-based diagnosis for complex genomic and DNA methylation changes1R41TR005388-01 | CHEN, YI-WEN | D4Z4 MEDICINE, INC., MD | $313,372 | ZRG1 |
| 2025 | Anti-sense oligonucleotide inhibitors of retinoic acid signaling and reversion of retinal remodeling for mitigating vision loss1R41EY036319-01A1 | OCONNOR, STEVE | SHIFT PHARMACEUTICALS HOLDINGS, INC., MO | $312,239 | ZRG1 |
| 2025 | Vector mediated anti-vascular and anti-inflammatory therapy for AMD1R41EY036318-01A1 | GILGER, BRIAN CHIRSCH, MATTHEW LOUIS | BEDROCK THERAPEUTICS, INC., NC | $310,952 | ZRG1 |
| 2025 | Controlling NETosis to Treat Diabetic Wounds.1R41DK142247-01 | TAN, TAO | HTIC, INC., VA | $310,438 | ZRG1 |
| 2025 | Intraoperative Sensor to Comprehensively Measure Ligament Engagement During Knee Arthroplasty1R41AG093459-01 | LIZALEK, LESLEY | TENSENSE LLC, WI | $308,927 | ZRG1 |
| 2025 | AAV-CRISPR engineering brown-like adipocytes targeting obesity and metabolic disorders1R41DK142538-01 | LIU, YONGXING "JAMES" | UNITED BIOTHERAPEUTICS LLC, NJ | $307,508 | ZRG1 |
| 2025 | sxRNA-Select: Using RNAs for Positive Selection of Cell Lines, Enabling High-Yield Biotherapeutic Production1R41GM157947-01 | TENENBAUM, SCOTT | SXRNA TECHNOLOGIES, INC., NY | $307,257 | ZRG1 |
| 2025 | Approaches to enable large scale heparin bio-manufacturing1R41HL177991-01 | BALAGURUNATHAN, KUBERANCAPILA, ISHAN | BIOPARIN, LLC, UT | $306,656 | ZRG1 |
| 2025 | Bioinformatics pipeline for personalized diagnostics of transplant rejection1R41AI189162-01 | BARSKI, ARTEM | DATIRIUM, LLC, OH | $306,500 | ZRG1 |
| 2025 | Cell type-specific gene therapy approach for TOMT-linked congenital hearing loss1R41DC022471-01 | CUNNINGHAM, CHRISTOPHER LTZOUNOPOULOS, THANOS | ECHOGENESIS THERAPEUTICS INC, PA | $305,628 | ZRG1 |
| 2025 | Phonocath - An endovascular medical device to objectively evaluate Pulsatile Tinnitus1R41DC022504-01 | AMANS, MATTHEW | VDF INDUSTRIES INC, CA | $305,197 | ZRG1 |
| 2025 | Engineered Memory T cells as a Platform to Treat Enzymopathies1R41AI184248-01A1 | SHIRKEY-SON, NICOLE J. | KOMMODO HOLDINGS CORP., MN | $304,838 | ZRG1 |
| 2025 | Preclinical Development of LCTG-001, a Human Secretory IgA Replacement Therapy for CVID Patients1R42AI188865-01 | MANE, VIRAJ PRAMOD | LACTIGA US INC., NJ | $304,629 | ZRG1 |
| 2025 | Use a humanized monoclonal antibody as an emergency prophylactic and therapeutictreatment against human Q fever1R41AI188656-01 | ZHANG, GUOQUAN | ZENVAX, LLC, TX | $301,674 | ZRG1 |
| 2025 | Bispecific antibody targeting IgE-producing B cells for treating allergic diseases1R41AI188995-01 | MA, ZHENGYU | CELLERGY PHARMA, DE | $300,000 | ZRG1 |
| 2025 | ND Enabling Studies for CMT-101, a Novel Gene Therapy for Glycogen Storage Disease 1b1R42DK141304-01A1 | HAWKINS, ALLEE, YOUNGMOK | COMETA THERAPEUTICS INC, MD | $299,648 | ZRG1 |
| 2025 | Epigenetic editor therapeutics1R41GM157863-01 | FEDULOV, ALEXEY V | EPIGENTER, LLC, RI | $298,530 | ZRG1 |
| 2025 | Zinc nanocrystals from zinc tetraammine fluoride for caries arrest and remineralization1R41DE034627-01 | LI, XINSAXENA, DEEPAK | PERIOMICS CARE, LLC, NY | $297,711 | ZRG1 |
| 2025 | Automated Microfluidics: Advancing Cell Culturing through Non-Sacrificial Analysis and Heterogeneous Microenvironments1R41GM154567-01A1 | VORONOV, ROMAN S | ALTVIVO, INC., OK | $295,038 | ZRG1 |
| 2025 | Bioengineering strategies for exogenic organ production1R41HL174447-01A1 | GARRY, DANIEL J. | NORTHSTAR GENOMICS, LLC, MN | $279,750 | ZRG1 |
| 2024 | Development of negative allosteric modulators of the mu-opioid receptor for the management of opioid use disorder2R42DA056254-02 | TRAYNOR, JOHN R. | ELEVEN THERAPEUTICS CORP, CA | $1,567,215 | ZRG1 |
| 2024 | A Robust Platform for Design and Development of Therapeutic Peptides for Metabolic Syndrome2R42DK131842-02 | BEINBORN, MARTINKUMAR, KRISHNA | VELUM, INC., MA | $1,135,509 | ZRG1 |
| 2024 | An automated device for quantifying DNA damage2R44ES030274-02 | COOKE, MARCUS STANLEYROSS, CHRISTOPHER | ENGINEERING RESOURCES GROUP, INC., FL | $1,047,828 | ZRG1 |
| 2024 | Development of a Peptide-Drug Conjugate for Topically Treating the Viral Skin Disease Molluscum Contagiosum2R42AI162385-03 · under PA-22-178 | RICCIARDI, ROBERT PAUL | FOX CHASE CHEMICAL DIVERSITY CENTER, INC, PA | $1,039,551 | ZRG1 |
| 2024 | A New Small-Molecule Kinase Inhibitor for Airway Disease2R42HL149523-02 · under PA-22-178 | BROSCHAT, KAY O | NUPEAK THERAPEUTICS, INC., MO | $1,018,383 | ZRG1 |
| 2024 | Establishing the market-readiness of an in vivo technology for assessing drug toxicity-induced tissue damage2R42GM140538-02 | JOHNSON, STEVEN EDWARD | DURAMETRIX LLC, WI | $1,011,661 | ZRG1 |
| 2024 | Prevention of corneal transplant rejection using AAV-BDRK-401 therapy2R42EY031625-02 · under PA-22-178 | GILGER, BRIAN CHIRSCH, MATTHEW LOUIS | BEDROCK THERAPEUTICS, INC., NC | $975,387 | ZRG1 |
| 2024 | A New Anti-inflammatory Therapy for Ischemic Stroke2R42HL156322-02A1 · under PA-22-178 | LIANG, BRUCE | CORNOVUS PHARMACEUTICALS, INC., CT | $934,548 | ZRG1 |
| 2024 | Development of an integrated smartphone-nanosensor platform for onsite biomonitoring of exposure to pesticides2R42ES032388-02A1 · under PA-22-178 | WANG, JUN | NANODIAGNOSTIC TECHNOLOGY, LLC, NC | $915,031 | ZRG1 |
| 2024 | An accurate, affordable, and transferable assay for minimally invasive detection of esophageal squamous cell carcinoma (ESCC) in Africa and the United States2R42CA261376-02A1 | LAUN, SARAH | CAPSULOMICS, LLC, MD | $885,000 | ZRG1 |
| 2024 | A Novel Non-Invasive Method of Dysphagia Detection in Preterm Infants: Bottle Finalization & Validation2R42HD104305-02 | MCGRATTAN, KATLYN ELIZABETH | NUBORN MEDICAL, INC., MN | $859,275 | ZRG1 |
| 2024 | Automated microfluidic device for blood analysis in neonates2R42HD100251-02 · under PA-22-178 | GONZALEZ-SUAREZ, ALAN M | SERSENSE, INC., MN | $780,138 | ZRG1 |
| 2024 | Detection of extracellular vesicles in urine for diagnosis of preeclampsia2R42HD096993-02A1 | STYBAYEVA, GULNAZ | SERSENSE, INC., MN | $780,138 | ZRG1 |
| 2024 | Clinical performance testing of neuropacs in Parkinsonism diagnosis2R42NS132614-02 | BARMPOUTIS, ANGELOS | AUTOMATED IMAGING DIAGNOSTICS, LLC, FL | $736,624 | ZRG1 |
| 2024 | Development of a Novel AAV9 Gene Replacement Therapy for Neurofibromatosis Type 21R41NS135883-01 · under PA-22-178 | HENWOOD, NICOLENAEIMI KARAROUDI, MEISAM | MERLIN THERAPEUTICS INC, PA | $699,559 | ZRG1 |
| 2024 | Development of a Novel Aspiration Pump for Neurointerventional Procedures1R41NS134425-01A1 | HANSER, MANNINGSTARKE, ROBERT MICHAEL | VON MEDICAL, INC, FL | $693,385 | ZRG1 |
| 2024 | STTR Phase II - Development of a visual-to-tactile conversion system for automating the tactile graphic generation process2R42EY031628-02A1 · under PA-22-178 | PALANI, HARI PRASATH | UNAR LABS, LLC, ME | $674,598 | ZRG1 |
| 2024 | Non-catalytic FAK inhibitors as novel therapeutics for lung fibrosis2R42HL162392-02 | KNOX, KENNETH SMARLOWE, TIMOTHY A | FAKNOSTICS, LLC, AZ | $673,796 | ZRG1 |
| 2024 | Anatomic Imaging Derived 4D Hemodynamics using Deep Learning1R42HL174259-01A1 | ALLEN, BRADLEY DAVID | THIRD COAST DYNAMICS, INC., IL | $656,751 | ZRG1 |
| 2024 | A Novel Xenon Delivery Platform for Cerebroprotection During Stroke2R42NS098918-04 | BOOHER, KEITHHUANG, SHAOLING | ZYMO RESEARCH CORPORATION, CA | $631,721 | ZRG1 |
| 2024 | BREATH: Breakthrough Research in Electromyography for the Assessment of Sleep-disordered BreaTHing1R42HL176325-01 | KOOLA, JEJO DAVIDMANDEVILLE, ROSS | POWELL MANSFIELD, INC., CA | $615,621 | ZRG1 |
| 2024 | Development of highly parallelized interferometric near-infrared spectroscopy for the real-time non-invasive measurement of cerebral blood flow1R41NS137832-01 | KHOLIQOV, OYBEK | NEURALENZ, INC, NY | $498,995 | ZRG1 |
| 2024 | Novel brain-penetrant drugs for translation-targeting therapeutics of Alzheimer’s disease1R41AG085859-01 · under PA-22-178 | CHEN, XIAN | TRANSCHROMIX, LLC., NC | $497,218 | ZRG1 |
| 2024 | Lumbo-venous CSF Shunt for Treatment of Communicating Hydrocephalus.1R41NS135749-01A1 | BRINJIKJI, WALEED | CONWAY MEDICAL LLC, MN | $492,983 | ZRG1 |
| 2024 | Dual-function Carbon Modified-Silicon Microelectrodes for Biomolecule Detection with Fast Scan Cyclic Voltammetry and Electrophysiology Recording and Stimulation1R41MH139088-01 | ZESTOS, ALEXANDROS GEORGE | SPIKE NEURO LLC, MI | $491,579 | ZRG1 |
| 2024 | CD4-LINK: Improving access to HIV care in underserves areas with a home-based, mail-in CD4 count test1R41MH138179-01 | FAHLBERG, MARISSAVACCARI, MONICA | SPOTTED TECH LLC, LA | $449,093 | ZRG1 |
| 2024 | Single telomere length analysis using DNA array and FISH: a low-cost and accurate test for telomere-associated diseases1R41AG085701-01 · under PA-22-178 | WANG, YINGZHENG, YUN-LING | TELOHEALTHDX LLC, MD | $448,961 | ZRG1 |
| 2024 | Flexible, scalable, and generalizable photogrammetric head modeling for high-density diffuse optical tomography1R41MH138258-01 | TROBAUGH, JASON WAYNE | ESPERIMAGE LLC, MO | $446,490 | ZRG1 |
| 2024 | High-throughput Direct Sequencing and Quantitative Mapping of RNA Modifications using Mass Spectrometry.1R41HG013624-01 | ZHANG, SHENGLONG | DIRECTSEQ BIOSCIENCES, INC., NJ | $406,500 | ZRG1 |
| 2024 | Preventing chemotherapy-related toxicities and infections with a novel phosphorylated triblock copolymer1R41CA287593-01 · under PA-22-178 | ALVERDY, JOHN CHENNESSEY, PATRICK | COVIRA SURGICAL, IL | $400,000 | ZRG1 |
| 2024 | Development of a novel, RNA-interference-based therapeutic to treat prostate cancer1R41CA287846-01A1 | PETER, MARCUS E.SCHICKEL, ROBERT | NUAGO THERAPEUTICS INC, IL | $400,000 | ZRG1 |
| 2024 | The Development of Radiolabeled PSMA Agent with Low Salivary Gland Uptake1R41CA285188-01A1 | WU, ZHANHONG | TRIPILL BIOTECHNOLOGY, CORP., NC | $399,981 | ZRG1 |
| 2024 | Stroma-penetrating nanomedicine to improve treatment for pancreatic cancer1R41CA278033-01A1 · under PA-22-178 | EICHINGER, KATHERINE MARIE | DUO ONCOLOGY INC, PA | $399,970 | ZRG1 |
| 2024 | Preclinical Studies to Develop an Eya2 Tyr Phosphatase Inhibitor as a Novel Medulloblastoma Therapeutic1R41CA291231-01A1 | FORD, HEIDE L.WANG, XIANGZHAO, RUI | SIEYAX, INC, CO | $399,709 | ZRG1 |
| 2024 | Engineered Glioblastoma-specific T cells using Immunostimulatory Photothermal Nanoparticles1R41CA287488-01A1 | FERNANDES, ROHANSWEENEY, ELIZABETH E | IMMUNOBLUE, LLC, MD | $399,669 | ZRG1 |
| 2024 | 1,3-Thioureas as First In Class Mitochondrial Inhibitors to Treat Oral Cancer1R41DE034719-01A1 | GONZALES, CARA B | KERACEUTICALS, INC., TX | $399,635 | ZRG1 |
| 2024 | Innovations to expand and accelerate the commercial impact of DNA modifications1R41HG013877-01 | TOMEK, KYLE | DNALI DATA TECHNOLOGIES, INC., NC | $399,538 | ZRG1 |
| 2024 | Multi-Modality Optical Molecular Imaging System for Preclinical Cancer Models1R42CA287798-01 · under PA-22-178 | GULSEN, GULTEKINMOY, AUSTIN | TRIFOIL IMAGING, CA | $399,491 | ZRG1 |
| 2024 | Innovative Point-of-Care Solutions for Long-term Alcohol Biomarkers1R41AA031429-01 · under PA-22-178 | NEILSEN, PAUL O | ECHELON BIOSCIENCES, INC., UT | $399,293 | ZRG1 |
| 2024 | Development of a highly sensitive DNA hypermethylation-based kit to identify Barrett's esophagus patients at high risk of progressing to esophageal adenocarcinoma1R41CA291354-01 | ZHOU, ZHONGREN | PRE-CANCER DIAGNOSIS, LLC, NJ | $398,738 | ZRG1 |
| 2024 | Development of a Novel Aqueous Humor-Based Multiplex Assay for Uveal Melanoma Metastatic Risk Prediction1R41CA291243-01A1 | XU, LIYA | OLMEDA BIOSCIENCES LLC, CA | $396,161 | ZRG1 |
| 2024 | Proactive Dual-Irrigation Cardiac Chest Tube to Maintain Postoperative Patency1R41HL176288-01 | PISTINER, JAKETSCHABRUNN, CORY MICHAEL | CIRCULATECH LLC, FL | $392,119 | ZRG1 |
| 2024 | Antibody-based prertargeted alpha particle therapy for ovarian cancer1R42CA287696-01 · under PA-22-178 | HOUGHTON, JACOBSCHULTZ, MICHAEL KING | VIEWPOINT MOLECULAR TARGETING, INC., IA | $391,553 | ZRG1 |
| 2024 | TT-036 for the treatment of scleroderma-associated pulmonary fibrosis1R41HL176277-01 | FEGHALI-BOSTWICK, CAROL A. | THENDOR THERAPEUTICS LLC, SC | $389,754 | ZRG1 |
| 2024 | Clutter-GO: Facilitating Delivery and Adherence in Evidence-Based Treatment for Hoarding Disorder via a Patient-Provider Digital Health Tool1R41MH138146-01 | ADAMS LARSEN, MARGOWHEATON, MICHAEL GRADY | VIRTUALLY BETTER, INC., GA | $386,266 | ZRG1 |
| 2024 | Extending shelf life and preserving the nutritional value of freezer-stored breastmilk1R41HD115506-01 | SILPE, JUSTIN E | PUMPKIN BABY INC., NJ | $378,188 | ZRG1 |
| 2024 | Laser-guided drug delivery to prevent tumor recurrences1R41EB036383-01 | HAEMMERICH, DIETER | ONCOBLAZE LLC, SC | $374,095 | ZRG1 |
| 2024 | Custom Accessories for Breastfeeding Success1R41HD115477-01 | KAIR, LAURA R | CBEZ, LLC, CA | $373,877 | ZRG1 |
| 2024 | Cilia Biomarker Kit Development for Brain Injury Diagnosis and Prognosis.1R41NS139906-01A1 | RAMCHANDRAN, RAMANI | CIAN, INC., WI | $369,886 | ZRG1 |
| 2024 | Development of a mobile harm reduction treatment for alcohol use disorder (mHaRT-A)1R41AA031393-01 · under PA-22-178 | COLLINS, SUSAN E | HART3S - A SOCIAL PURPOSE CORPORATION, WA | $369,597 | ZRG1 |
| 2024 | Optimizing Antibody Production in CHO Cells Using Epi-MAX Technology to Increase Heavy and Light Chain Expression1R41TR005122-01 | BEGLEY, THOMAS JBYRNE, SHANE | CODOMAX INC., MA | $350,000 | ZRG1 |
| 2024 | Metabolism and Mitochondrial Energetics Therapy for Septic Shock1R42GM151928-01A1 | ALAM, HASAN B | MEDOSOME BIOTEC, LLC, FL | $350,000 | ZRG1 |
| 2024 | Platform technology to identify and develop first-in-class anti-fibrotic therapeutics through inhibition of collagen CP4H1R42HL176297-01 | LENNOX, RONALDSILVER, RANDI BETH | ADIUTRIX THERAPEUTICS, NY | $350,000 | ZRG1 |
| 2024 | Designer Pichia Strains That Enable Difficult-To-Express Biologics Production by Addressing Limitations in Secretory Protein Expression1R41TR005278-01 | BYRNE, SHANEFRIED, STEPHEN DAVID | CODOMAX INC., MA | $350,000 | ZRG1 |
| 2024 | A Nanofluidic/Microfluidic System for Enhanced Low-Input and Single-Cell Proteomics1R41GM156144-01 | TIMPERMAN, AARON T | FLUIDISPEC LLC, PA | $350,000 | ZRG1 |
| 2024 | Developing an Anti-proteotoxicity Therapy for Neurodegenerative Diseases1R41NS137860-01 | ZHANG, TAO | REZIGENE, LLC, MD | $349,854 | ZRG1 |
| 2024 | A novel platform for targeted radiopharmaceuticals for imaging and therapy of ovarian cancer1R41CA291316-01 | LAPI, SUZANNE ELIZABETH | ONCURIE INC., NC | $349,808 | ZRG1 |
| 2024 | LF-TIMING: Large-scale label-free profiling of cell-cell interactions1R42TR005299-01 | BERDEAUX, REBECCA LROYSAM, BADRINATH | CELLCHORUS INC., TX | $349,171 | ZRG1 |
| 2024 | Next-generation Tissue-Adhesive Endoscopic Tattoo Ink1R41DK142564-01 | REGE, KAUSHAL | ENDOTAT BIOTECHNOLOGIES LLC, AZ | $343,000 | ZRG1 |
| 2024 | Engineering Chemically Modified RNPs for Effective Treatment of Angelman Syndrome1R41NS134480-01A1 | XIE, YING | COURAGENE, INC., NJ | $339,999 | ZRG1 |
| 2024 | Precision medicine for pancreatic cancer. Biomarker-guided drug delivery of platinum to tumors1R41CA287830-01A1 | FARRELL, NICHOLAS PATRICKTREVINO, JOSE G. | BIOPLATINUM TECHNOLOGIES, LLC, VA | $338,828 | ZRG1 |
| 2024 | Novel Therapeutic for Kidney Failure: A Modified, Water-Soluble Orally-Active Caveolin-1 Scaffolding Domain Peptide with Improved Characteristics for Drug Development1R41DK141315-01 | HOFFMAN, STANLEY R | FIBROTHERAPEUTICS, INC., SC | $337,740 | ZRG1 |
| 2024 | All-in-one measurement and exercise respiratory strength trainer with biofeedback and adherence tracking capability.1R41HL176339-01 | ZAMBRANA, NELSON | NOVIS PRODUCTS, LLC, FL | $333,810 | ZRG1 |
| 2024 | A versatile platform to isolate cells from three-dimensional samples after spatial and temporal profiling1R41GM154612-01 | LEE, JIHWANST-PIERRE, FRANCOIS | IMAGEN BIOWORKS INC., TX | $333,048 | ZRG1 |
| 2024 | Novel Urine Collection Kit for Obstructive Sleep Apnea1R41HL170893-01A1 | BURNS, CHRISTOPHER THOMAS | PGXL TECHNOLOGIES, LLC, KY | $328,047 | ZRG1 |
| 2024 | Novel Paxillin-FAK Inhibitors for the Treatment of Liver Fibrosis1R42DK141379-01 | FALLON, MICHAEL BMARLOWE, TIMOTHY APARK, HYO-JIN | FAKNOSTICS, LLC, AZ | $325,976 | ZRG1 |
| 2024 | Tethered Enzyme Technology for PoC and At-home Real-time Monitoring of Liver Function1R41TR004880-01 · under PA-22-178 | COHEN, ROYFISCHELL, DAVID | TET MEDICAL, NY | $324,962 | ZRG1 |
| 2024 | A Stand Alone Wearable for Tracking Environmental Exposure and Evaluating Respiratory Response1R41HL174172-01 | CHAPMAN, TERRY | CANAIRY LLC, AL | $324,770 | ZRG1 |
| 2024 | Design of Calcium-sensing Receptor Targeted Thera(g)nostic Agents1R41DK139927-01A1 | GOODMAN, MARK MYRONMARICHEV, KOSTIANTYNYANG, JENNY J. | INLIGHTA BIOSCIENCES, LLC, GA | $323,743 | ZRG1 |
| 2024 | Optimizing Dual Therapy for Chronic Prostatitis/Chronic Pelvic Pain Syndrome1R41DK139835-01 | SARGENT, WILLIAM QTHUMBIKAT, PRAVEEN | DOLOR THERAPEUTICS, LLC, IL | $318,488 | ZRG1 |
| 2024 | Novel Integrated Platform to Quantitate Rejuvenation in vivo1R41AG085951-01 · under PA-22-178 | EGAN, BRIAN STANLEYJELINEK, MARY ANNETERSKIKH, ALEXEY V | ACTIVE MOTIF, INC., CA | $314,262 | ZRG1 |
| 2024 | Engineered gamma delta T cells for systemic correction of dystrophic epidermolysis bullosa1R41AR083760-01A1 | SHIRKEY-SON, NICOLE J. | KOMMODO THERAPEUTICS LLC, MN | $313,370 | ZRG1 |
| 2024 | Rapid Dehydration and Stabilization of Biopharmaceutical Formulations at Room Temperature1R41TR004571-01A1 · under PA-22-178 | MEZHERICHER, MAKSIM | INAEDIS, INC, NJ | $312,634 | ZRG1 |
| 2024 | A Deep Learning-based Platform for the Remote Management andAnalysis of Diabetic Foot Ulcers1R41DK139941-01A1 | BHASIN, MANOJ | ANXOMICS LLC, GA | $312,492 | ZRG1 |
| 2024 | Enhanced Prosthetic Vascular Graft Function by Local Release of Nitric Oxide1R41HL176245-01 | GARREN, MARK RICHARD STEPHENSHEBUSKI, RONALD J. | NYTRICX INC., GA | $311,824 | ZRG1 |
| 2024 | Computational design and evaluation of peptide-guided protein degraders1R41GM153081-01 · under PA-22-178 | CAMARGO, LUIZ MIGUEL QUINN | UBIQUITX, INC., NY | $306,872 | ZRG1 |
| 2024 | Next-generation nanoflow LC column technology to enable high sensitivity proteomics of limited samples1R41GM156145-01 | IVANOV, ALEXANDER R | MIXEDLCMEDIA LLC, MA | $306,860 | ZRG1 |
| 2024 | AI Enabled App for Fracture Reduction Prediction in Pediatrics1R41AR084997-01 | CLEARY, KEVIN R. | MIRA MEDICAL, LLC, MD | $306,858 | ZRG1 |
| 2024 | Novel Selective SGLT-1 Inhibitors for Adjunctive Therapy for Cystic Fibrosis Associated Metabolic Diseases1R42DK141338-01 | REED, JESSICAXU, JIE | GENETOBE INC., MI | $306,779 | ZRG1 |
| 2024 | Efficient low flow pump for pediatric extracorporeal membrane oxygenation1R41HL176259-01 | CLEARY, KEVIN R. | MIRA MEDICAL, LLC, MD | $306,643 | ZRG1 |
| 2024 | Microdosing Implant to Mitigate Depression Associated with Opioid Use Disorder1R41EB036916-01A1 | HEATH, KATIEWALKER, GLENN MADISONWERFEL, THOMAS A | INTERVAL THERAPEUTICS LLC, MS | $306,556 | ZRG1 |
| 2024 | Development of a Novel Therapeutic Agent for Skin Fibrosis1R41AR084935-01 | BOGATKEVICH, GALINA SSILVER, RICHARD M. | FIBROBIOLOGICS, LLC, SC | $306,518 | ZRG1 |
| 2024 | Development of Small Molecule Biomarker-Based Diagnostics for Bacterial Vaginosis1R41AI176963-01A1 · under PA-22-178 | SRINIVASAN, SUJATHA | METABOLITEDX CORP, WA | $306,500 | ZRG1 |
| 2024 | Restoring Tolerance with an Oral AMPK Agonist Nanomedicine Targeting Intestinal Dendritic Cells as a Preventative Therapy for Type 1 Diabetes1R41AI186895-01 | CARGILL, CHRISTINA PAIGE | QRONO, INC, PA | $306,500 | ZRG1 |
| 2024 | Innovative oral regenerative therapy leveraging immunoregenerative mechanisms.1R41DE033573-01 · under PA-22-178 | GOUDY, STEVEN L | ORIDIVUS LLC, GA | $306,499 | ZRG1 |
| 2024 | Restoring Tolerance in Inflammatory Bowel Disease with an Oral AMPK agonist Nanomedicine that Targets Antigen Presenting Cells.1R41DK142311-01 | CARGILL, CHRISTINA PAIGE | QRONO, INC, PA | $306,468 | ZRG1 |
| 2024 | Multi-functional magnetic nanorods for constructing theranostic extracellular vesicles for treating myocardial infarction1R41HL169102-01A1 · under PA-22-178 | LI, YUANCHENGLIU, GUANSHU | 5M BIOMED, LLC, GA | $306,433 | ZRG1 |
| 2024 | Novel Small Molecule Therapeutic for Vitiligo1R41AR084965-01 | MCCALL, KELLY | AOHBIO CORPORATION, OH | $306,278 | ZRG1 |
| 2024 | Epigenetic phenotyping from liquid biopsy for preeclampsia risk classification during the first trimester1R41HL172464-01 · under PA-22-178 | REICHEL, JONATHAN | KANONA, INC., NJ | $306,223 | ZRG1 |
| 2024 | Diamond quantum sensor for magnetoencephalography1R41EB036583-01 | ACOSTA, VICTOR MARCELJARMOLA, ANDREJS | ODMR TECHNOLOGIES, INC., CA | $305,000 | ZRG1 |
| 2024 | Multi-omic CSF Assay for the Diagnosis of Brain Cancers1R42NS135834-01 · under PA-22-178 | BETTEGOWDA, CHETANCOE, BRIAN | BELAY DIAGNOSTICS, LLC, IL | $303,845 | ZRG1 |
| 2024 | Meganuclease-mediated gene editing for durable control of HSV-2 infection1R41AI186683-01 | JEROME, KEITH R | CALADAN THERAPEUTICS, INC., AL | $303,731 | ZRG1 |
| 2024 | Proof of concept studies for in vivo produced CAR-T cells that target B cell follicles as a treatment for HIV1R41AI184054-01 | ATHANASIOU, MARIA CONSTANCESCHMIDT, DANIEL | MARPAM PHARMA, LLC, MN | $302,248 | ZRG1 |
| 2024 | Chimeric antigen receptor (CAR) T cell therapy for severe allergic diseases.1R41AI177157-01A1 · under PA-22-178 | MA, ZHENGYU | CELLERGY PHARMA, DE | $300,000 | ZRG1 |
| 2024 | Proof of concept experiments for T3SS inhibitors against burn wound infections1R41AI183900-01 | OPPERMAN, TIMOTHY J. | MICROBIOTIX, INC, MA | $300,000 | ZRG1 |
| 2024 | Preclinical Development of Occidiofungin for Treatment of Oral and Dermal Candidiasis1R42AI184022-01 | SMITH, JAMES LEIF | SANO CHEMICALS, INC, TX | $300,000 | ZRG1 |
| 2024 | A Compliant Superhydrophobic Antimicrobial Photodynamic Therapy Bandage for the Prevention of Multidrug Resistant Wound Infections1R41AI183969-01 | XU, QIANFENG | SINGLETO2 THERAPEUTICS, LLC, NJ | $300,000 | ZRG1 |
| 2024 | Leptospiral VM Protein Antigen Detection for Rapid Diagnosis of Leptospirosis1R41AI181135-01A1 | CHAURASIA, REETIKA | LUNA BIOSCIENCE, INC., CT | $300,000 | ZRG1 |
| 2024 | Discovery and development of novel schistosomicidal agents1R41AI184237-01 | PETUKHOV, PAVEL | ACHEMINALL CORPORATION, IL | $300,000 | ZRG1 |
| 2024 | Developing a Potent Broad-Spectrum Prophylactic for Tickborne Disease1R41AI179571-01A1 | WYCOFF, KEITH | PLANET BIOTECHNOLOGY, INC., CA | $300,000 | ZRG1 |
| 2024 | A broad spectrum anti-gonorrhea immunotherapeutic1R41AI179576-01A1 | LEWIS, LISA ANNSHAUGHNESSY, JUTAMASWYCOFF, KEITH | PLANET BIOTECHNOLOGY, INC., CA | $300,000 | ZRG1 |
| 2024 | Targeting fungal ceramide synthases as new antifungals1R41AI186554-01 | DEL POETA, MAURIZIO | MICRORID TECHNOLOGIES, INC., NY | $300,000 | ZRG1 |
| 2024 | Inhalable dry powders of mycobacteriophages for tuberculosis therapy1R41AI186644-01 | WARNKEN, ZACHARY N | VIA THERAPEUTICS, LLC, TX | $300,000 | ZRG1 |
| 2024 | The development of a GMP eDHFR vector to monitor investigational CAR T cell therapies1R41AI186797-01 | MILLER, DEREKSELLMYER, MARK A | VELLUM BIOSCIENCES LLC, PA | $300,000 | ZRG1 |
| 2024 | Liposome-displayed peptide vaccine against disseminated candidiasis by clinically-relevant Candida species1R41AI184019-01A1 | XIN, HONG | POP BIOTECHNOLOGIES, INC, NY | $300,000 | ZRG1 |
| 2024 | A Novel, Host-Directed Therapeutic for the Treatment of Sulfur Mustard Induced Lung Injury1R41AI187083-01 | VERESS, LIVIA AGNES | CMTX BIOTECH, INC., NY | $299,993 | ZRG1 |
| 2024 | Dendritic cell therapy for GvHD1R41AI179340-01A1 | KNIGHT, KATHERINE L.OSBORNE, BARBARA A | HASENTECH, INC., IL | $299,989 | ZRG1 |
| 2024 | Development of Inhibitors Against SARS CoV-2 NSP16 Methyltransferase1R41AI177149-01A1 · under PA-22-178 | LI, HONGMIN | LYCHEE BIOSCIENCE LLC, AZ | $299,985 | ZRG1 |
| 2024 | HBI-002 for Cystic Fibrosis1R41HL167404-01A1 | BRUSCIA, EMANUELA MARINAGOMPERTS, EDWARD | HILLHURST BIOPHARMACEUTICALS, INC., CA | $299,975 | ZRG1 |
| 2024 | The mosquito salivary protein AgBR1 as vaccine candidate against Chikungunya1R41AI186794-01 | FIKRIG, EROL | L2 DIAGNOSTICS, LLC, CT | $299,969 | ZRG1 |
| 2024 | Development of a Pan-COVID-19 Vaccine Candidate1R41AI181134-01 · under PA-22-178 | HU, HAITAO | RNA THERAPEUTICS INC., DE | $299,967 | ZRG1 |
| 2024 | Develop natural compound emodin as a novel therapy for calcific aortic valve disease1R41HL172481-01 · under PA-22-178 | AZHAR, MOHAMAD | ACEPRE, LLC, SC | $299,953 | ZRG1 |
| 2024 | A novel therapeutic for Lyme arthritis based on a secretory leukocyte protease inhibitor1R41AI186833-01 | FIKRIG, EROL | L2 DIAGNOSTICS, LLC, CT | $299,933 | ZRG1 |
| 2024 | Manganese-based MRI contrast agent for quantitative myocardial perfusion imaging1R41HL174406-01 | SONG, ALLEN W | LADERX LLC, NC | $299,932 | ZRG1 |
| 2024 | Chimeric Ligands for Induced Proximity (CLIP) platform for targeted proteome editing and upregulation of antigen presentation1R41AI186686-01 | CAMARGO, LUIZ MIGUEL QUINN | UBIQUITX, INC., NY | $299,921 | ZRG1 |
| 2024 | Delivery of a candidate AgTRIOVx malaria vaccine by thermostable microneedle patches1R41AI184218-01 | ANTHONY, KAREN G. | L2 DIAGNOSTICS, LLC, CT | $299,878 | ZRG1 |
| 2024 | A Biosinpired Genetically-Expressible Dual-Modality Peptide-Based Probe for Super-Resolution Correlative Light and Electron Microscopy1R41GM153173-01 · under PA-22-178 | LAWRENCE, CHARLES MARTINLEWIS, KEVIN MICHAEL | PHOTON BIOSCIENCES, LLC, WA | $299,812 | ZRG1 |
| 2024 | A Multivalent mRNA Vaccine to Prevent Transmission of Tick-bornePathogens1R41AI179587-01A1 | FIKRIG, EROLNARASIMHAN, SUKANYA | L2 DIAGNOSTICS, LLC, CT | $298,362 | ZRG1 |
| 2024 | High Throughput Screening to Discover Bacterial DNA Gyrase Poisoning Inhibitors1R41TR005250-01 | LENG, FENFEI | TOP BIOSCIENCES, LLC, FL | $298,045 | ZRG1 |
| 2024 | Enhancing Peripheral Nerve Repair with an Injectable Recombinant Polypeptide Scaffold1R41NS135845-01A1 | CHILKOTI, ASHUTOSHROBERTS, STEFAN | INSOMA BIO, INC., NC | $296,151 | ZRG1 |
| 2024 | MECHANICALLY ROBUST 3D-PRINTED MICROCAPILLARY NEEDLES WITH ANTI-CLOGGING CAPABILITIES1R41GM153053-01 · under PA-22-178 | RAND, KINNERET | SEETRUE TECHNOLOGY, LLC, MD | $296,043 | ZRG1 |
| 2024 | Vectorless supercoiled DNA: a new scalable abacterial in vitro system to improve gene therapy safety and production efficiency1R41GM154562-01 | BAI, HAIBO | CHESAPEAKE GENOMIC SYSTEMS LLC, MD | $295,924 | ZRG1 |
| 2024 | Optimization and Validation of Minimally-Invasive and Low-Cost Blood Collection Device for Lead Testing1R41ES036480-01 | AHUJA, PUNKAJFUNK, WILLIAM E | SKYWAY BIOSCIENCES, IL | $295,923 | ZRG1 |
| 2024 | Novel sorbents for removal of PFAS from water1R41ES036472-01 | CORONELL NIETO, ORLANDOLEIBFARTH, FRANK ALBERTWEITKAMP, ROBIN | SORBENTA INC, NC | $295,923 | ZRG1 |
| 2024 | PeriScope: A Novel Videoscope and Toolkit to Enable Fluoro-free Pericardial Access for Epicardial Ablation1R41HL174307-01 | BERUL, CHARLES IKUMTHEKAR, ROHANOPFERMANN, JUSTIN | PERICOR, LLC, MD | $295,922 | ZRG1 |
| 2024 | Targeting a disease-specific conformation of fibronectin as a novel approach for liver fibrosis treatment1R41DK138519-01A1 | SHETTY, JAGATHPALA | VASARYA THERAPEUTICS, INC., DE | $295,921 | ZRG1 |
| 2024 | RHODA: Rapid Hemoglobin-Oxygen Dissociation Assay1R41HL172662-01 · under PA-22-178 | GALEN, PETERGURKAN, UMUT A. | HEMEX HEALTH, INC., OR | $295,920 | ZRG1 |
| 2024 | Multifunctional coagulation and platelet profiling during cardiaccirculatory support1R41HL170886-01A1 | NADKARNI, SEEMANTINI K | COALESENZ INC., MA | $295,915 | ZRG1 |
| 2024 | Gene Therapy-mediated Angiogenesis to Enhance Survival of Transplanted Fat1R41HL170928-01A1 | CRYSTAL, RONALD G | ENYX THERAPEUTICS, LLC, NY | $295,901 | ZRG1 |
| 2024 | Pedi-Sync: A Clinical Decision Support Tool to Improve Oral Feeding Outcomes in Preterm Infants1R41HD113429-01A1 | BRADLEY, CAR | NEOCARE INNOVATIONS, INC., CA | $295,897 | ZRG1 |
| 2024 | Feasibility of Electronic Screening to Identify Risk of Opioid Misuse and Overdose1R41DA060000-01 · under PA-22-178 | FERRARESE, NICK | OPREMS LLC, IL | $295,876 | ZRG1 |
| 2024 | High-performance BPA-free dental restoration composites with remineralization capabilities1R41DE033937-01A1 | STANSBURY, JEFFREY W. | CALLENTIS CONSULTING GROUP LLC, TX | $295,689 | ZRG1 |
| 2024 | Evaluation of siRNA based drugs as pro-regenerative disease-modifying therapeutics for age-related olfactory loss1R41DC021592-01 · under PA-22-178 | SCHWOB, JAMES E.WYNNE, GRAHAM MICHAEL | RHINO THERAPEUTICS INC, DE | $295,662 | ZRG1 |
| 2024 | Plasmonic Scattering Microscopy for high-throughput in-situ quantification of molecular binding kinetics on single cells1R42GM154550-01A1 | LY, NGUYEN | BIOSENSING INSTRUMENT, INC., AZ | $295,561 | ZRG1 |
| 2024 | Antigen and adjuvant selection for a vaccine against urogenital schistosomiasis, Hematoshield1R41AI181069-01 · under PA-22-178 | GRAY, SEAN ALEXMOLEHIN, ADEBAYO J | PAI LIFE SCIENCES, INC., WA | $295,386 | ZRG1 |
| 2024 | Targeting PFKFB3 kinase for activation of cell competition and elimination of dysfunctional beta-cells in type-2 diabetes1R41DK139901-01 | GREEFF, OPPEL | METANOIA BIO LLC, CA | $295,257 | ZRG1 |
| 2024 | Novel Acquisition and Computation of Cardiac Functions in Developing Zebrafish Embryos1R41HL166096-01A1 | CAO, HUNGLAU, MICHAEL P.H. | SENSORIIS, INC., WA | $294,993 | ZRG1 |
| 2024 | Capless mRNA for use as a vaccine1R41AI179367-01A1 | FOUTY, BRIAN W | COMPOVAX, LLC, AL | $294,877 | ZRG1 |
| 2024 | Low-Cost Ultrasound Imaging for In-Home, Rural, and Clinic Care Without The Need For Trained Staff1R41EB034646-01A1 · under PA-22-178 | DAHL, JEREMYRAGHAVAN, RAGHU | SONOVANCE, INC., MD | $294,641 | ZRG1 |
| 2024 | Manufacturable Biomimetic Microfluidic Oxygenator for Safer, Simpler Treatment of Respiratory Failure1R42HL170864-01A1 | ASTOR, TODDBORENSTEIN, JEFFREY T. | BIOMEMBRETICS, INC., MA | $294,063 | ZRG1 |
| 2024 | Lifelong Correction of Hereditary Tyrosinemia Type 1 and Other Monogenic Liver Diseases using Liver-specific Hydrodynamic Gene Delivery through the Biliary System1R42DK141297-01 | KUMBHARI, VIVEK | HYDROGENE THERAPEUTICS INC, TX | $293,987 | ZRG1 |
| 2024 | Developing novel Type 1 CRISPR tools for gene editing therapy1R41GM153041-01 · under PA-22-178 | HOU, ZHONGGANG | GENETOBE INC., MI | $293,319 | ZRG1 |
| 2024 | Pre-operative planning for surgical treatment of patellar instability1R41AR083757-01A1 | CLARY, CHADDFITZPATRICK, CLARE | ORTHO HAUS LLC, CO | $292,954 | ZRG1 |
| 2024 | Natural Electrospun Scaffolds as an Alternative to Synthetic Mesh for Stress Urinary Incontinence1R41DK139872-01A1 | THOMSON, REBECCA | NOVAGYN LLC, NH | $292,752 | ZRG1 |
| 2024 | Targeting retinoid acid metabolic pathways to treat noise-induced hearing loss1R41DC021394-01 · under PA-22-178 | DIAZ, PHILIPPE J | DERMAXON, LLC, MT | $290,920 | ZRG1 |
| 2024 | Repurposing of FDA-approved Nrf2 Activators as a Novel Inhaled Therapy for Pulmonary Fibrosis1R41HL174346-01 | HECKER, LOUISE | FIBRONOX, L.L.C., AZ | $286,739 | ZRG1 |
| 2024 | Development of a novel kit for reduction of aerosolized particles during endonasal surgeries: the PharynVac Device1R41EB035980-01 | ILORETA, ALFRED-MARCRAPOPORT, BENJAMIN ISAAC | PHARYNVAC SURGICAL TECHNOLOGY INC., NY | $285,705 | ZRG1 |
| 2024 | MyDocSaid: Deep Learning for Patient-Centric Record, Summarization, and Analysis of Medical Conversations1R41NR021089-01 · under PA-22-178 | MARHAMATI, NINA | POTENTIA ANALYTICS INC, IL | $284,317 | ZRG1 |
| 2024 | Development of Neutralizing Antibodies to Machupo Virus1R41AI186830-01 | MARUYAMA, TOSHIAKISAPHIRE, ERICA OLLMANN | ABWIZ BIO, INC., CA | $280,769 | ZRG1 |
| 2024 | Development of VBI-1 as a novel treatment protocol for outpatient cardiac arrest1R41HL174360-01 | SIMPKINS, CUTHBERT ORMONDWACKER, MICHAEL | VIVACELLE BIO, INC., IN | $279,569 | ZRG1 |
| 2024 | Personal Cooling Garments to Protect at-Risk Patients from Extreme Heat Waves1R41HL172682-01 · under PA-22-178 | IHNFELDT, ROBIN | GENERAL ENGINEERING AND RESEARCH, LLC, CA | $275,765 | ZRG1 |
| 2024 | Development and in vivo validation of a machine learning platform to predict ototoxic potential of pharmaceuticals1R41DC021390-01 · under PA-22-178 | HARKNESS, JOHN H | REWIRE NEUROSCIENCE, LLC, OR | $275,737 | ZRG1 |
| 2024 | Safety of AAV-mediated C1 Esterase Inhibitor Gene Therapy for Hereditary Angioedema1R41AI181097-01 · under PA-22-178 | CRYSTAL, RONALD G | ENYX THERAPEUTICS, LLC, NY | $275,737 | ZRG1 |
| 2024 | A Novel Tool for Integrating Resident Preferences for Improving Service Delivery and Satisfaction in Long-term Care Settings1R41NR021462-01 | STERNS, ANTHONY | LINKED SENIOR, INC., DC | $275,621 | ZRG1 |
Showing the 200 most recent of 2,088 awards.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.